Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. N. Lubchenko
The Mechanisms of Acquired Resistance to Anti-Egfr Drugs in Non-Small Cell Lung Cancer Not Associated With T790m Mutation and Their Significance in Clinical Practice
Advances in molecular oncology
Related publications
Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer
Experimental Hematology and Oncology
Cancer Research
Oncology
Hematology
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation
Cancers
Cancer Research
Oncology
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology
Cancer Research
Oncology
Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer
Annals of Oncology
Medicine
Oncology
Hematology
P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients With Non-Small Cell Lung Cancer Who Received Icotinib Progress
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Primary Concomitant EGFR T790M Mutation Predicted Worse Prognosis in Non-Small Cell Lung Cancer Patients
OncoTargets and Therapy
Oncology
Pharmacology
Newly Emergent Acquired EGFR Exon 18 G724S Mutation After Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-Cell Lung Cancer: A Case Report
OncoTargets and Therapy
Oncology
Pharmacology
P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
